Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers (HV), antispike immunoglobulin G (IgG) was detected in 88% of IDP after dose 2, increasing to 93% by 6 months after dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed one-third that of HV. IgG binding to Omicron BA.1 was lowest among variants. Angiotensin-converting enzyme 2 pseudo-neutralization only modestly correlated with antispike IgG concentration. IgG levels were not significantly altered by receipt of different messenger RNA–based vaccines, immunomodulating treatments, and prior severe acute respiratory syndrome coronavirus 2 infections. While our data show that three doses of coronavirus disease 2019 vaccinations induce antispike IgG in most IDP, additional doses are needed to increase protection. Because of the notably reduced IgG response to Omicron BA.1, the efficacy of additional vaccinations, including bivalent vaccines, should be studied in this population.
27 November 2023 in Open Forum Infectious Diseases
While some immune-deficient persons (IDP) face higher risk for severe SARS-CoV-2 infection than the general population, little is known about their immune response to post-vaccination infections. A cohort of 217 IDP and 54 healthy volunteers (HV) were followed from April 2021 to April 2023. Blood was collected at baseline, 1-, and 6-months post vaccination. Anti-spike IgG response was assessed by ELISA and the T cell receptor repertoire was sequenced. SARS-CoV-2 infection was actively monitored for 6 months post-vaccination; participants could self-report at any point. Swimmer plot of breakthrough infections relative to SARS-CoV-2 waves in the US. Spike IgG titers by SARS-CoV-2 status at sample Immune Deficient Persons (IDP) who were SARS-CoV-2 positive had significantly higher titers at multiple timepoints, while Healthy Volunteers (HV) only showed different titers by SARS-CoV-2 status at 6 months post-doses 2 and 3. Despite reporting high preventative behavior to avoid SARS-CoV-2, IDP experienced post-vaccination infections at a similar rate as HV, mostly during the Omicron period. Less than half of IDP have received a bivalent booster. Additional doses, especially the bivalent dose, enhances the immune response in this population. This research was supported by the Division of Intramural Research, NIAID, NIH. All Authors: No reported disclosures